NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse

Leukemia Research

Volumn 35, Issue 7, 2011, Pages

  Clarke, Sarah ^a   O'Reilly, John ^a   Romeo, Giuliana ^a   Cooney, Julian ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CHROMOSOME PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMATINIB; NUP214 ABL1 PROTEIN; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BACKACHE; CASE REPORT; CHROMOSOME 9Q; CHROMOSOME INSERTION; COUGHING; DRUG EFFICACY; DRUG RESPONSE; EXON; FATALITY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMOGLOBIN BLOOD LEVEL; HIP PAIN; HUMAN; KARYOTYPE EVOLUTION; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOBLAST; MALE; MYALGIA; NUP214 ABL1 FUSION GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SORE THROAT; SPLENOMEGALY; T CELL LEUKEMIA; THROMBOCYTE COUNT;

ADULT; ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PORE COMPLEX PROTEINS; PIPERAZINES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 79958722344     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.025     Document Type: Letter

References (6)

1. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084-1089.
2. Graux C., Stevens-Kroef M., Lafage M., Dastugue N., Harrison C.J., Mugneret F., et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 2009, 23:125-133.
3. Ballerini P., Busson M., Fasola S., van den Akker J., Lapillione H., Romana S.P., et al. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 2005, 19:468-470.
4. Quintas-Cardama A., Tong W., Manshouri T., Vega F., Lennon P.A., Cools J., et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008, 22:1117-1124.
5. Stergianou K., Fox C., Russell N.H. Fusion of NUP214 to ABL1 on amplified episomes in T-ALL - implications for treatment. Leukemia 2005, 19:1680-1681.
6. Deenik W., Beverloo H.B., van der Poel-van de Luytgaarde S.C., Wattel M.M., van Esser J.W., Valk P.J., et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 2009, 23:627-629.